These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37664260)

  • 1. The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021.
    Al-Ahmari TS; Alotaibi AF; Aljasser AI; Aljasser AI; Eldaw AM; Abd-Ellatif EE
    Cureus; 2023 Aug; 15(8):e42780. PubMed ID: 37664260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond genotype-4: Direct-acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia.
    Ismail MH
    Health Sci Rep; 2024 Jan; 7(1):e1795. PubMed ID: 38186940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia.
    Alarfaj SJ; Alzahrani A; Alotaibi A; Almutairi M; Hakami M; Alhomaid N; Alharthi N; Korayem GB; Alghamdi A
    Saudi Pharm J; 2022 Oct; 30(10):1448-1453. PubMed ID: 36387341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia.
    Hashim A; Almahdi F; Albaba EA; Barkia O; Alkasam R; Almahmoud A; Nabil A; Alsulaimani A; Mosli M
    J Epidemiol Glob Health; 2020 Jun; 10(2):178-183. PubMed ID: 32538035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological Perspectives: A Four-Year Insight Into Hepatitis C Surveillance in the Kingdom of Saudi Arabia.
    Almajid A; Albarbari H; Bazroon A; Al-Awami H; Aljurayyad R; Albadran R; Alkhamis Z; Alomair H; Aljishi Y
    Cureus; 2024 Jan; 16(1):e52646. PubMed ID: 38249649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis.
    Shah I; Ahmad W; Qadir A; Muhammad I; Islam M; Shah M; Jan N; Anjum S
    Cureus; 2021 Nov; 13(11):e19768. PubMed ID: 34950547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
    Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
    World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C.
    Abdulla M; Al Ghareeb AM; Husain HAHY; Mohammed N; Al Qamish J
    World J Clin Cases; 2022 Dec; 10(34):12566-12577. PubMed ID: 36579085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.
    Ryu JE; Song MJ; Kim SH; Kwon JH; Yoo SH; Nam SW; Nam HC; Kim HY; Kim CW; Yang H; Bae SH; Song DS; Chang UI; Yang JM; Lee SW; Lee HL; Lee SK; Sung PS; Jang JW; Choi JY; Yoon SK
    Korean J Intern Med; 2022 Sep; 37(5):958-968. PubMed ID: 35981893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants.
    Natali KM; Jimenez HR; Slim J
    J Pharm Pract; 2022 Jun; 35(3):495-499. PubMed ID: 33317381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease.
    Alqahtani SA; Broering DC; Alghamdi SA; Bzeizi KI; Alhusseini N; Alabbad SI; Albenmousa A; Alfaris N; Abaalkhail F; Al-Hamoudi WK
    BMC Gastroenterol; 2021 Jun; 21(1):245. PubMed ID: 34074270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Hill A; Khoo S; Fortunak J; Simmons B; Ford N
    Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia.
    El-Hazmi MM
    Saudi Med J; 2004 Jan; 25(1):26-33. PubMed ID: 14758374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
    Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
    Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries.
    Barber MJ; Gotham D; Khwairakpam G; Hill A
    J Virus Erad; 2020 Sep; 6(3):100001. PubMed ID: 33251019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.